Alnylam Pharmaceuticals (ALNY) is a publicly traded Healthcare sector company. As of May 20, 2026, ALNY trades at $296.14 with a market cap of $38.22B and a P/E ratio of 122.46. ALNY moved +1.41% today. Year to date, ALNY is -26.46%; over the trailing twelve months it is +0.84%. Its 52-week range spans $205.87 to $495.55. Analyst consensus is strong buy with an average price target of $452.73. Rallies surfaces ALNY's financials, insider trades, hedge fund holdings, congressional trades, analyst ratings, and AI-generated research below.
Alnylam slips after Q1 results despite $1.04B product revenue and guidance reiteration: Alnylam shares fell 3.08% to $300.94 as investors digested the company’s April 30, 2026 Q1 results and updates. Despite 121% net product revenue growth to $1.036 billion and reiterated 2026 revenue guidance of $4.9–$5.3 billion, the stock pulled back after the release.
| Metric | Value |
|---|---|
| Price | $296.14 |
| Market Cap | $38.22B |
| P/E Ratio | 122.46 |
| EPS | $2.39 |
| Dividend Yield | 0.00% |
| 52-Week High | $495.55 |
| 52-Week Low | $205.87 |
| Volume | 603.28K |
| Avg Volume | 0 |
| Revenue (TTM) | $3.71B |
| Net Income | $313.75M |
| Gross Margin | 81.77% |
18 analysts cover ALNY: 0 strong buy, 15 buy, 3 hold, 0 sell, 0 strong sell. Consensus rating is strong buy. Average price target: $452.73.